# US 2025/0144253 A1 · 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144253 A1
- Document ID: US20250144253A1
- Status: Published application
- Kind: A1
- Application number: 18/716,251
- Filed: 2022-12-05
- Published: 2025-05-08
- Earliest claimed: 2021-12-06
- Assignees: Helmholtz-Zentrum Dresden-Rossendorf E.V.
- Applicants: Helmholtz-Zentrum Dresden-Rossendorf E.V.
- Inventors: Sven STADLBAUER; Fabian KRUTZEK; Klaus KOPKA
- Web page: https://patentgrep.com/patent/US20250144253A1

## CPC

- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- C07D 405/14: containing three or more hetero rings
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of general formula I where Z is selected from the group containing a group of general formula II, a group of general formula III, a group of general formula IV, a group of general formula V, a group of general formula VI, and a group of general formula VIa:

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A compound of general formula I
wherein
R1 is selected from the group consisting of hydrogen, a substituted or unsubstituted C1-C6 alkyl group and bromine;
R2 is selected from the group consisting of a substituted or unsubstituted C1-C6 alkyl group and bromine or iodine;
R3 is selected from the group consisting of chlorine, bromine, iodine and a first leaving group AG1;
M is hydrogen or a group R5;
X is C—H or N, with the provision that at most two of the moieties X are N and the remaining moieties X are C—H;
Y is selected from the group consisting of —CN, —S(O)2—CH3, fluorine, iodine and a second leaving group AG2;
Z is selected from the group consisting of a group of general formula II, a group of general formula III, a group of general formula IV, a group of general formula V, a group of general formula VI and a group of general formula VIa
AG1 is selected from the group consisting of an organotin group, a boronic acid and a boronic acid ester;
AG2 is selected from the group consisting of an organotin group, a fluorosulphate group, a boronic acid and a boronic acid ester;
R4 is a sulphonic acid group or a phosphonic acid group;
R5 is selected from a first group or a second group, wherein
the first group consists of a group of general formula VII or a group of general formula VIII:
X1 is C—H or N,
M2 is a chelate ligand or a chelate complex consisting of the chelate ligand and a central atom, wherein the central atom is selected from the group consisting of Sc-43, Sc-44, Sc-47, Cu-61, Cu-62, Cu-64, Cu-67, Ga-68, Y-86, Zr-89, Y-90, Tc-99m, In-111, La-133, Gd-153, Gd-155, Gd-157, Tb-149, Tb-152, Tb-155, Tb-161, Lu-177, Pd-197m, Pb-209, Pb-212, Bi-213, and Ac-225, m is an integer of 0 to 3, n is an integer of 1 to 7, and p is an integer of 1 to 4;
the second group consists of a group of general formula IX, a group of general formula X, a group of general formula XI, and a group of general formula XII:
wherein
R6 is O-Ts or fluorine and R7 is O-Tf or fluorine, Ts designates a tosyl group and Tf designates a triflyl group.

### Claim 17 (depends on 16)

The compound according to claim 16, wherein R6 and R7 are [18F]fluorine.

### Claim 18 (depends on 16)

The compound according to claim 16, wherein Z is a group of general formula III or IV

### Claim 19 (depends on 18)

The compound according to claim 18, wherein R4 is a sulphonic acid group.

### Claim 20 (depends on 16)

The compound according to claim 16, wherein R5 is selected from a group of general formula IX, X, or XII:

### Claim 21 (depends on 20)

The compound according to claim 20, wherein R6 and R7 are fluorine.

### Claim 22 (depends on 20)

The compound according to claim 20, wherein R6 and R7 are [18F]fluorine.

### Claim 23 (depends on 16)

The compound according to claim 16, wherein R5 is selected from the group of general formula VII or VIII:

### Claim 24 (depends on 23)

The compound according to claim 23, wherein m is 0 or 1, n is 1 or 2, and p is 1 or 2.

### Claim 25 (depends on 23)

The compound according to claim 23, wherein M2 is a chelate ligand that is selected from the group consisting of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra acetic acid group (DOTA group), a 1,4,7-triazacyclononane-1-glutaric acid-1,4,7-acetic acid group (NODAGA group), and a 6,6′-((1,4,10,13-tetraoxa-7,16-diazacyclooctadecane-7,16-diyl)bis(methylene))dipicolinic acid group (MACROPA group).

### Claim 26 (depends on 23)

The compound according to claim 23, wherein M2 is a chelate complex the central atom of which is selected from the group consisting of Cu-64, Ga-68, and Lu-177.

### Claim 27 (depends on 16)

The compound according to claim 16 for use as a medicament.

### Claim 28 (depends on 16)

The compound according to claim 16 for use as a medicament for the diagnostics and therapy of diseases in which the protein programmed cell death 1 ligand 1 (PD-Li) is involved.

### Claim 29 (depends on 27)

The compound according to claim 27, wherein the medicament is for the diagnostics and/or therapy of cancer diseases and COVID-19 infections.

### Claim 30 (depends on 16)

A medicament containing a compound according to claim 16 or a pharmaceutically acceptable salt thereof.
